Get the Daily Brief
Latest Biotech News
Mayo Clinic study: neoadjuvant chemo raises survival in early pancreatic cancer
A Mayo Clinic analysis of more than 1,400 early‑stage pancreatic cancer patients found that administering chemotherapy before surgery (neoadjuvant therapy) significantly improved overall survival...
Oak Ridge tool cracks microbial defense codes — speeds bioengineering
Oak Ridge National Laboratory released software that decodes microbial defense mechanisms, cutting a key microbe‑engineering workflow from about a week to hours. The tool automates steps to bypass...
IRB Barcelona unveils Spain’s first integrated spatial omics platform
IRB Barcelona inaugurated Spain’s first comprehensive Spatial Omics Platform to support high‑resolution mapping of cells within intact tissues. The facility brings together technologies for...
Histone lactylation drives immune escape in pancreatic cancer
A Nature Communications study identified histone lactylation as an epigenetic mechanism that promotes immune evasion in pancreatic ductal adenocarcinoma by upregulating the chemokine CXCL1....
Lilly bets on in vivo CAR‑T: Orna deal worth up to $2.4B
Eli Lilly agreed to acquire Orna Therapeutics in a deal valued at up to $2.4 billion to add an in vivo CAR‑T platform based on engineered circular RNA and lipid nanoparticles. Lilly said Orna’s...
FDA rejects Regenxbio’s Hunter syndrome gene therapy — regulator flags endpoints
The FDA issued a complete response letter rejecting Regenxbio’s RGX‑121 gene therapy for Hunter syndrome, citing concerns about patient population definition, reliance on a natural history control...
Wegovy legal fight escalates: Novo sues Hims as FDA warns on copycats
Novo Nordisk sued telehealth firm Hims & Hers for alleged patent infringement over semaglutide (Wegovy), seeking damages it described as potentially in the 'hundreds of millions.' Novo accused...
FDA clears Yescarta label change: primary CNS lymphoma no longer contraindicated
The FDA updated the label for axicabtagene ciloleucel (Yescarta), removing the prior contraindication for treating patients with primary central nervous system (CNS) lymphoma. The agency approved...
Roche’s BTK shock: fenebrutinib edges Ocrevus in PPMS data
Roche released phase‑3 results showing its BTK inhibitor fenebrutinib achieved non‑inferiority versus Ocrevus (ocrelizumab) in primary progressive multiple sclerosis (PPMS), cutting the risk of...
Shingles shot tied to lower dementia risk: large observational study
A study published in Nature Communications reported an association between the recombinant zoster vaccine (RZV) and a statistically significant reduction in dementia risk. Researchers analyzed...
First‑in‑human immune cell therapy posts encouraging safety, activity in lymphoma
MD Anderson reported first‑in‑human data for RB‑1355, an engineered immune cell therapy tested in relapsed or refractory non‑Hodgkin lymphoma. The initial study showed acceptable safety and...
Medable launches Agentic AI: PI‑focused tool for clinical outcome review
Medable rolled out an Agentic AI product designed to support principal investigators in assessing electronic clinical outcome assessment data. The tool automates reconciliation tasks, surfaces...
Takeda taps Iambic for AI drug discovery — multiyear small‑molecule pact
Takeda signed a multiyear R&D collaboration with San Diego AI biotech Iambic to apply generative and predictive models to small‑molecule programs across oncology, gastrointestinal, and...
QuantX secures $85M Series B: Big Pharma VCs back immunology push
QuantX Biosciences raised $85 million in a Series B led by Lilly and Sanofi Ventures to advance its China‑American pipeline focused on popular immunology targets. The financing will support R&D,...
Lilly snaps up Orna: $2.4B bet on in vivo CAR‑T
Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion to secure the company’s circular RNA platform for in vivo CAR‑T therapies. Lilly said Orna’s lead program, ORN‑252, a...
Medable unveils Agentic AI... PI oversight in focus
Medable launched an "Agentic AI" product designed to help principal investigators (PIs) manage and assess electronic clinical outcome assessment (eCOA) data. The company says the agent is...
FDA vows crackdown: mass-marketing of copycat drugs in the crosshairs
FDA Commissioner Marty Makary pledged swift enforcement against companies mass‑marketing unapproved copycat drugs after telehealth firm Hims announced a compounded semaglutide pill claimed to...
Waters completes BD deal – acquired diagnostics unit underperformed
Waters Corporation closed its $18.8 billion transaction to combine with Becton Dickinson’s Biosciences & Diagnostic Solutions business, but reported that the acquired unit missed Q4 revenue...
Takeda inks multiyear AI pact with Iambic – small‑molecule push
Takeda signed a multiyear collaboration with San Diego AI biotech Iambic to apply generative AI for small‑molecule discovery across oncology, gastrointestinal and inflammation targets. The...
Fenebrutinib edges Ocrevus – phase 3 shows 12% cut in progression risk
Roche presented phase 3 data showing its BTK inhibitor fenebrutinib reduced the risk of disability progression by 12% versus Ocrevus in primary progressive multiple sclerosis (PPMS), meeting...